MetLife Investment Management LLC Purchases 3,716 Shares of Cabot Co. (NYSE:CBT)

MetLife Investment Management LLC boosted its holdings in Cabot Co. (NYSE:CBT - Free Report) by 6.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 61,965 shares of the specialty chemicals company's stock after purchasing an additional 3,716 shares during the period. MetLife Investment Management LLC owned about 0.11% of Cabot worth $5,658,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. R Squared Ltd bought a new stake in shares of Cabot in the 4th quarter worth approximately $26,000. EverSource Wealth Advisors LLC raised its stake in shares of Cabot by 37.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 808 shares of the specialty chemicals company's stock valued at $74,000 after buying an additional 219 shares during the period. GAMMA Investing LLC raised its stake in shares of Cabot by 10.7% in the fourth quarter. GAMMA Investing LLC now owns 1,348 shares of the specialty chemicals company's stock valued at $123,000 after buying an additional 130 shares during the period. Manchester Capital Management LLC lifted its position in shares of Cabot by 1,685.1% during the 4th quarter. Manchester Capital Management LLC now owns 1,678 shares of the specialty chemicals company's stock valued at $153,000 after buying an additional 1,584 shares during the last quarter. Finally, KBC Group NV grew its stake in shares of Cabot by 43.1% during the 4th quarter. KBC Group NV now owns 2,046 shares of the specialty chemicals company's stock worth $187,000 after acquiring an additional 616 shares during the period. Institutional investors own 93.18% of the company's stock.

Analyst Ratings Changes

Several research firms have commented on CBT. StockNews.com raised shares of Cabot from a "hold" rating to a "buy" rating in a report on Thursday, April 17th. Mizuho dropped their target price on Cabot from $122.00 to $110.00 and set an "outperform" rating on the stock in a research report on Tuesday, January 7th. JPMorgan Chase & Co. reduced their price target on Cabot from $105.00 to $85.00 and set an "underweight" rating for the company in a research report on Friday, February 21st. Finally, UBS Group dropped their price objective on Cabot from $93.00 to $83.00 and set a "neutral" rating on the stock in a report on Monday, April 7th.

Cabot Price Performance

Shares of NYSE:CBT traded up $0.21 on Tuesday, hitting $79.18. The company's stock had a trading volume of 55,595 shares, compared to its average volume of 389,275. The company has a market capitalization of $4.29 billion, a PE ratio of 10.52, a PEG ratio of 0.74 and a beta of 1.04. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.00 and a quick ratio of 1.29. The company has a 50-day simple moving average of $81.74 and a 200 day simple moving average of $93.34. Cabot Co. has a 1 year low of $73.63 and a 1 year high of $117.46.

Cabot (NYSE:CBT - Get Free Report) last announced its earnings results on Monday, February 3rd. The specialty chemicals company reported $1.76 earnings per share for the quarter, beating analysts' consensus estimates of $1.74 by $0.02. Cabot had a net margin of 10.60% and a return on equity of 26.79%. Sell-side analysts forecast that Cabot Co. will post 7.57 EPS for the current fiscal year.

Cabot Profile

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.